GA-PT&C-FORENSICS
9.12.2014 12:01:18 CET | Business Wire | Pressemeddelelse
PT&C Forensics, Inc. (DBA PT&C Forensic Consulting Services, P.A.), a leading provider of forensic engineering services to the insurance claims industry, today announced that it has acquired global forensic engineering firm, LWG Consulting, Inc.
Based in Northbrook, Illinois, LWG is a leader in forensic engineering, with over 20 offices and more than 100 engineers and expert consultants located around the world. Since 1984, LWG has provided equipment damage assessment and accident investigation and failure analysis services to the Property/Casualty insurance industry and attorneys. In addition, LWG’s TekPro Global division provides industry-leading equipment restoration services. The acquisition positions PT&C/LWG as the preeminent global forensic engineering firm.
With this acquisition, PT&C addresses the growing demand by insurance claims and legal professionals for a global, multi-disciplinary and highly-skilled forensic engineering partner. PT&C’s depth of experience managing fire and explosion investigations and civil/structural engineering incidents complemented by LWG’s core capabilities in electrical, mechanical and energy equipment losses creates a market-leading forensic engineering platform offering the comprehensive array of services to the insurance and legal communities.
On the acquisition, Grover Davis, President and CEO of PT&C Forensics, comments, “LWG possesses a highly-skilled, global team of engineers and experts. Their strength in niche service offerings such as equipment losses, digital forensics and restoration, paired with a corporate culture built upon delivering superior customer service, made LWG an extremely attractive partner for us. I am confident that the combined 50 years of experience shared by PT&C and LWG leadership will enable delivery of unequivocal engineering expertise to our clients.”
Robert Wedoff, President and CEO of LWG Consulting added, “Given that LWG was built upon similar values, it was easy for us to embrace PT&C’s demonstrated long-term vision of building a great, people-centric company dedicated to providing outstanding service. I am incredibly excited not only about the value we can create together for our clients, but for the opportunities that we can provide for our team members across the entire platform.”
About PT&C Forensic Consulting Services, P.A.
PT&C, a wholly-owned subsidiary of Engle Martin & Associates, is based in Atlanta, GA. Service offerings include forensic engineering, fire and explosion investigations, building consulting, catastrophe response and products liability testing. Staffed with over 100 engineers and experts in over 40 cities across the United States, PT&C provides extensive experience to insurance claims, legal and law enforcement professionals. Their depth of experience ranges from residential structural failure evaluations and vehicle fire investigations to large complex commercial losses.
Contact:
PT&C Forensics, Inc.
Brooke Trosclair, 888-782-3473
Vice
President
brooke.trosclair@PTCforensics.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum